Dr Elissa Jp Foster, DO | |
3500 Gaston Ave, Dallas, TX 75246-2017 | |
(214) 820-2361 | |
Not Available |
Full Name | Dr Elissa Jp Foster |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 3500 Gaston Ave, Dallas, Texas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356803530 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Elissa Jp Foster, DO 3500 Gaston Ave, Dallas, TX 75246-2017 Ph: () - | Dr Elissa Jp Foster, DO 3500 Gaston Ave, Dallas, TX 75246-2017 Ph: (214) 820-2361 |
News Archive
DARA BioSciences, Inc. announced that it has initiated a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. The study will enroll approximately 75 volunteers and will be conducted at Quintiles' Overland Park facility.
Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.
Genetics can help determine whether a person is likely to quit smoking on his or her own or need medication to improve the chances of success, according to research published in today's American Journal of Psychiatry. Researchers say the study moves health care providers a step closer to one day providing more individualized treatment plans to help patients quit smoking.
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company's plan to regain compliance with the Exchange's continued listing standards, as submitted by the Company in June.
› Verified 4 days ago